What factors drove the changes in Cytosorbents's revenue and profit?

What does Cytosorbents do and what are its main business segments?

What were the key takeaways from Cytosorbents’s earnings call?

What were the key takeaways from Cytosorbents's earnings call?

What is the market's earnings forecast for Cytosorbents next quarter?

What is Cytosorbents's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Cytosorbents year over year?

What is Cytosorbents's gross profit margin?

- **Revenue Growth**: 4% YoY to $37.1M, driven by international expansion (13% direct, 11.4% distributor) despite Germany decline.
- **Profitability**: Gross margin 71% (74% Q4), with path to cash flow breakeven in H2 2026 via cost cuts and inventory optimization.
- **Innovation Momentum**: 100+ PuriFi units placed globally; HotSwap gains strong clinician feedback.
- **FDA Progress**: Streamlined DrugSorb-ATR resubmission expected post-FDA alignment; STAR-T trial validation published.
- **Germany Recovery**: Restructured sales team shows early signs of improvement with Q1 pipeline activity.

**【CEO Summary Section】**
- Full-year 2025 revenue reached $37.1 million, up 4% YoY, driven by 13% growth in direct international sales and 11.4% in distributor sales. Germany sales declined 10% to $11.8 million due to restructuring.
- Gross margin improved to 71% for the year and 74% in Q4, reflecting manufacturing efficiencies.
- Launched PuriFi (standalone hemoperfusion pump) and HotSwap (cartridge exchange innovation), with over 100 PuriFi units placed globally.
- Clinical evidence shows CytoSorb reduces inflammatory markers and improves outcomes in sepsis; 75% of surveyed physicians use it for blood purification.
- DrugSorb-ATR progress: FDA appeal provided path for resubmission; STAR-T trial published in JTCVS, showing safety and reduced bleeding in CABG patients.
- Early signs of improvement in Germany with increased pipeline activity and engagement.

**【CFO Financial Commentary】**
- Q4 2025 revenue $9.2 million (1% YoY growth), with gross margin 74% vs. 71% YoY.
- Operating expenses $41.2 million for the year, flat vs. 2024, with $500k Q4 restructuring charge.
- Operating loss improved 10% to $14.7 million; adjusted EBITDA loss $10.5 million.
- Cash position $7.8 million, with $2.5 million debt proceeds offset by $3.8 million operating cash burn.
- Projected to achieve cash flow breakeven in H2 2026 through cost reductions and inventory management.

**【Q&A Key Highlights】**
- **FDA DrugSorb-ATR Update**: Interactive discussions with FDA to align on submission requirements; no timeline yet but focused on avoiding prior pitfalls.
- **Germany Turnaround**: Restructured sales team showing early momentum; Q1 2026 activity suggests incremental improvement.
- **Gross Margin Outlook**: Target 71-74% range, with potential upside from volume growth.
- **PuriFi Strategy**: Subsidized pump deployment to drive future disposable cartridge sales, similar to printer cartridge model.
- **Breakeven Path**: Workforce reductions and production efficiency improvements expected to reduce cash burn to breakeven by H2 2026.

Cytosorbents Corporation(CTSO)-20260326-2025 Q4 Earnings call transcript

- **Revenue Growth**: $9.5M Q3 (+10% YoY) driven by distributor and direct market expansion.
- **Profitability**: 70% gross margin stability, $2M EBITDA improvement YoY.
- **FDA Progress**: DrugSorb-ATR pre-submission meeting Q1 2026, potential approval mid-2026.
- **Cash Flow Management**: $2.5M immediate liquidity, 10% workforce reduction to achieve Q1 2026 breakeven.

**【CEO Opening Remarks】**
- Q3 2025 revenue of $9.5 million, +10% YoY, driven by distributor sales growth and direct market expansion outside Germany.
- Emphasized CytoSorb's 70% gross margin stability and $37M trailing 12-month core product sales.
- Highlighted German market restructuring with new leadership, simplified messaging, and targeted account strategy.
- DrugSorb-ATR FDA timeline update: pre-submission meeting Q1 2026, de novo filing Q1 2026, potential approval mid-2026.

**【CFO Financial Commentary】**
- Q3 2025 financials: 
  - Revenue $9.5M (+10% YoY)
  - Gross margin 70% (vs 61% prior year)
  - Operating expenses $9.5M (-6% YoY)
  - Adjusted EBITDA loss $2M (improved from $3.6M YoY)
- Implemented strategic workforce reduction (10% headcount) to achieve Q1 2026 cash flow breakeven.
- Secured $2.5M immediate funding and $2.5M contingent funding via amended loan agreement with Avenue Capital.

**【Q&A Highlights】**
- Gross margin outlook: 70%+ sustained with potential expansion via scale and DrugSorb commercialization.
- German sales restructuring metrics: tracking improved rep performance and efficiency KPIs.
- FDA pre-submission meeting objectives: clarify data requirements for de novo application.
- World Sepsis Day webcast generated 1000+ views and inquiries on CytoSorb sepsis treatment efficacy.

Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript

- **Revenue Momentum**: Q2 sales up 9% YoY, driven by 22% growth in Germany and strong distributor performance.
- **Regulatory Progress**: FDA appeal includes expert testimony; Health Canada reconsideration underway. Final decisions expected by year-end.
- **Sepsis Impact**: CytoSorb reduces septic shock mortality by 50%, with new clinical data supporting early, aggressive treatment.
- **Financial Focus**: Near breakeven for core business by year-end; $11.7 million cash on hand.
- **Margin Outlook**: Gross margin at 71%, with potential for improvement through production scale and DrugSorb launch.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 product sales of $9.6 million, up 9% YoY and 4% on a constant currency basis. Germany saw 22% YoY and sequential growth, while distributor sales were near record levels.
- **Gross Margin**: Held steady at 71%, though lower than Q2 2024 due to inventory write-offs.
- **DrugSorb ATR Regulatory Update**: FDA denied de novo application but appeal hearing included expert testimony and senior FDA review. Health Canada issued notice of refusal but reconsideration process underway. Final decisions expected by end of 2025.
- **CytoSorb in Sepsis**: New publications show CytoSorb reduces mortality in septic shock by 50% and improves hemodynamic stability. Global webinar on sepsis treatment scheduled for September 10.

**【CFO Financial Commentary】**
- **Net Income**: $1.9 million ($0.03/share) vs. $4.3 million loss in Q2 2024. Adjusted net loss of $3.7 million ($0.06/share).
- **Operating Expenses**: $10.4 million, up 3% YoY due to one-time costs ($400k for accounting rebuild, $200k regulatory consulting, $400k German restructuring).
- **Cash Position**: $11.7 million, with $1.7 million from tax credit sales. Net cash burn of $3.1 million in Q2.
- **Debt**: $15 million facility with $5 million tranche contingent on FDA approval.

**【Q&A Highlights】**
- **Regulatory Confidence**: CEO emphasized strength of appeal process and expert support for DrugSorb ATR. FDA response expected by end of August.
- **Germany Trends**: Reorganization progress positive, but ongoing work needed to optimize sales force efficiency.
- **Commercial Rollout**: Planned for 22 clinical trial sites plus select high-interest accounts, focusing on rapid access and reorder volume.
- **Gross Margin Outlook**: CFO sees potential for improvement through production efficiencies and higher-margin DrugSorb sales post-approval.

Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript

- **Q1 2025 sales stable**: $8.7M (-3% YoY), Germany restructuring impacting growth
- **Gross margin resilient**: 71% with plans for 2025 expansion
- **DrugSorb-ATR appeal filed**: FDA denial under review, potential 2025 resolution
- **$13.1M liquidity**: Shareholder offering strengthens balance sheet for launch
- **German recovery target**: H2 2025 return to growth after 2-year stagnation

**【CEO Opening Remarks】**
- Q1 2025 product sales: $8.7 million (-3% YoY), flat on constant currency. Germany sales down due to strategic reorganization, offset by strong international distributor performance.
- Gross margin held steady at 71%, targeting expansion in 2025 with higher production volumes.
- Key growth drivers: 
  1. New clinical data in septic shock
  2. Simplified 'early, aggressive, consistent' treatment messaging
  3. German market recovery (40% of sales)
  4. Dubai subsidiary expansion into MEA

**【CFO Financial Update】**
- Q1 2025 revenue: $8.7M (-3% YoY), gross margin 71% (vs. 76% in Q1 2024 due to lower production volumes).
- Operating expenses down 12% to $10.1M, net loss $1.5M (-76% YoY). 
- $6.8M raised via shareholder rights offering, total liquidity $13.1M as of Q1.
- Target: Core business near breakeven by H2 2025, supporting DrugSorb-ATR launch.

**【CMO Regulatory Update】**
- FDA denied DrugSorb-ATR de novo application but allowed formal appeal (due by June 24). 
- Canada review delayed but still expected in 2025.
- STAR registry data: 600+ patients, 0 device-related adverse events. Q1 2025 EuroPCR presentation shows reduced bleeding in CABG patients on Brilinta.

**【Q&A Highlights】**
- FDA appeal confidence: Strong data package, potential 60-day resolution.
- German market recovery: Reorganized sales team showing early Q2 signs of progress.
- Europe reimbursement: Active discussions in UK, focusing on cardiac surgery use case.
- Pipeline: Exclusive focus on DrugSorb-ATR launch preparation.

Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript

- **Core Business Resilience**: $35.6M CytoSorb sales (+15% YoY) with 71% gross margin; Germany reorganization to drive H2 2025 growth.
- **DrugSorb Breakthrough**: $300M U.S./Canada market opportunity with FDA/Health Canada decisions expected 2025; clinical data shows 50%+ bleeding reduction in CABG surgery.
- **Financial Turnaround**: 2024 operating loss down 47% to $16.7M; Q4 cash burn cuts 61% to $2.5M; $17M pro forma liquidity supports 2025 launch.
- **Key Risk**: Short-term Germany sales disruption (Q1 2025 down vs. 2024) to enable long-term growth.


**【CEO Summary Section】**
- **CytoSorb Core Business Growth**: 2024 product revenue reached $35.6 million (+15% YoY), driven by 28% growth in direct sales outside Germany and 22% growth in distributor sales. Germany sales remained flat due to market challenges, but a restructured sales team aims to restore growth in H2 2025.
- **DrugSorb-ATR Regulatory Momentum**: FDA De Novo application in interactive review; Health Canada submission under advanced review. Targeted $300M U.S./Canada market for CABG surgery on Brilinta patients, expandable to $1B+ as Brilinta generics emerge.
- **Clinical Evidence Strength**: 175-patient retrospective study showed CytoSorb doubled survival in septic shock; CTC Registry data validates early, aggressive treatment reduces mortality.
- **Financial Position**: Pro forma cash of $17M (incl. $7.3M from rights offering); $2.5M Q4 cash burn vs. $6.5M in Q4 2023. Core business targeting near breakeven by end-2025 to free up capital for DrugSorb launch.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Product revenue $9.2M (+25% YoY), gross margin 71%, operating loss $3.7M (-61% YoY). Adjusted EBITDA loss $2.4M (-70% YoY). Full-year product revenue $35.6M (+15% YoY), gross margin 71%.
- **Cost Efficiency**: 22% headcount reduction, $10.2M Q4 operating expenses (-30% YoY). 2024 operating loss $16.7M (-47% YoY). 
- **Liquidity**: $9.8M cash as of Dec 31; $12.3M liquidity boost from rights offering. Avenue Capital $20M debt facility provides additional runway.

**【Q&A Highlights】**
- **Regulatory Timeline**: FDA/Health Canada decisions expected 2025; no additional data requests identified. 
- **DrugSorb Launch Strategy**: Controlled market release at clinical trial sites to validate adoption, then scale with 15-25 direct reps + distributors. 
- **Breakeven Target**: Core business breakeven by end-2025 assumes modest revenue growth and 70%+ gross margins. DrugSorb launch in 2025 will require upfront investment but aims for 2026 profitability.
- **Germany Market Risk**: Short-term sales disruption from reorganization, but long-term growth potential remains significant.


Actual											-0.1	-0.08	-0.02	0	-0.1	-0.11	-0.15	-0.21	-0.21	-0.25	-0.28	-0.01	-0.17	-0.14	-0.21	-0.12	-0.12	-0.08	-0.04	-0.14	-0.02	0.03	-0.04	-0.07
Forecast											-0.135	-0.0833	-0.0957	-0.0401	-0.035	-0.05	-0.1215	-0.1253	-0.144	-0.1337	-0.165	-0.175	-0.1267	-0.1132	-0.1233	-0.1375	-0.12	-0.0975	-0.055	-0.05	-0.065	-0.05	-0.04	-0.055
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+25.93%	+3.96%	+79.10%	+100.00%	-185.71%	-120.00%	-23.46%	-67.60%	-45.83%	-86.99%	-69.70%	+94.29%	-34.18%	-23.67%	-70.32%	+12.73%	0.00%	+17.95%	+27.27%	-180.00%	+69.23%	+160.00%	0.00%	-27.27%

Actual	--	--	--	--	--	--	--	--	--	--	8.71M	9.79M	10.55M	12.00M	10.60M	12.02M	9.76M	10.78M	8.69M	8.50M	8.11M	9.40M	9.45M	9.42M	8.81M	8.70M	9.79M	9.89M	9.39M	9.20M	8.73M	9.62M	9.48M	9.23M
Forecast	--	--	--	--	--	--	--	--	--	--	6.96M	9.62M	9.49M	11.75M	11.51M	12.27M	9.70M	9.68M	9.72M	9.58M	8.97M	8.54M	8.74M	11.03M	9.50M	9.28M	9.80M	9.68M	10.36M	10.25M	9.21M	9.40M	10.40M	9.78M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+25.08%	+1.85%	+11.11%	+2.12%	-7.93%	-1.99%	+0.62%	+11.37%	-10.58%	-11.28%	-9.56%	+10.08%	+8.11%	-14.56%	-7.29%	-6.20%	-0.13%	+2.21%	-9.39%	-10.24%	-5.25%	+2.29%	-8.80%	-5.58%

CTSO

CTSO fundamentals

CTSO Q4 2025 Earnings

Earnings Call

You can ask Aime

CTSO

CTSO fundamentals

CTSO Q4 2025 Earnings

Earnings Call

CTSO Earnings Call Summary for Q4/20254:30 PM on Mar 25, 2026

CTSO Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

CTSO Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

CTSO Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

CTSO Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

You can ask Aime